CXCR2 and neoplasm: However, CAR T cells modified to express CXCR2 showed persistence in tumors and complete tumor regression in murine models of pancreatic cancer [125], suggesting that tumor-reactive immune cells can be modified to take advantage of the CXCR2 ligands in the tumor.